S Anazi,S Maddirevula,E Faqeih,H Alsedairy,F Alzahrani,H E Shamseldin,N Patel,M Hashem,N Ibrahim,F Abdulwahab,N Ewida,H S Alsaif,H Al Sharif,W Alamoudi,A Kentab,F A Bashiri,M Alnaser,A H AlWadei,M Alfadhel,W Eyaid,A Hashem,A Al Asmari,M M Saleh,A AlSaman,K A Alhasan,M Alsughayir,M Al Shammari,A Mahmoud,Z N Al-Hassnan,M Al-Husain,R Osama Khalil,N Abd El Meguid,A Masri,R Ali,T Ben-Omran,P El Fishway,A Hashish,A Ercan Sencicek,M State,A M Alazami,M A Salih,N Altassan,S T Arold,M Abouelhoda,S M Wakil,D Monies,R Shaheen,F S Alkuraya

Abstract:Intellectual disability (ID) is a measurable phenotypic consequence of genetic and environmental factors. In this study, we prospectively assessed the diagnostic yield of genomic tools (molecular karyotyping, multi-gene panel and exome sequencing) in a cohort of 337 ID subjects as a first-tier test and compared it with a standard clinical evaluation performed in parallel. Standard clinical evaluation suggested a diagnosis in 16% of cases (54/337) but only 70% of these (38/54) were subsequently confirmed. On the other hand, the genomic approach revealed a likely diagnosis in 58% (n=196). These included copy number variants in 14% (n=54, 15% are novel), and point mutations revealed by multi-gene panel and exome sequencing in the remaining 43% (1% were found to have Fragile-X). The identified point mutations were mostly recessive (n=117, 81%), consistent with the high consanguinity of the study cohort, but also X-linked (n=8, 6%) and de novo dominant (n=19, 13%). When applied directly on all cases with negative molecular karyotyping, the diagnostic yield of exome sequencing was 60% (77/129). Exome sequencing also identified likely pathogenic variants in three novel candidate genes (DENND5A, NEMF and DNHD1) each of which harbored independent homozygous mutations in patients with overlapping phenotypes. In addition, exome sequencing revealed de novo and recessive variants in 32 genes (MAMDC2, TUBAL3, CPNE6, KLHL24, USP2, PIP5K1A, UBE4A, TP53TG5, ATOH1, C16ORF90, SLC39A14, TRERF1, RGL1, CDH11, SYDE2, HIRA, FEZF2, PROCA1, PIANP, PLK2, QRFPR, AP3B2, NUDT2, UFC1, BTN3A2, TADA1, ARFGEF3, FAM160B1, ZMYM5, SLC45A1, ARHGAP33 and CAPS2), which we highlight as potential candidates on the basis of several lines of evidence, and one of these genes (SLC39A14) was biallelically inactivated in a potentially treatable form of hypermanganesemia and neurodegeneration. Finally, likely causal variants in previously published candidate genes were identified (ASTN1, HELZ, THOC6, WDR45B, ADRA2B and CLIP1), thus supporting their involvement in ID pathogenesis. Our results expand the morbid genome of ID and support the adoption of genomics as a first-tier test for individuals with ID.

Narrowing the Diagnostic Gap: Genomes, Episignatures, Long-Read Sequencing and Health Economic Analyses in an Exome-Negative Intellectual Disability Cohort

Utility of genome sequencing in exome‐negative pediatric patients with neurodevelopmental phenotypes

Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield

Next-generation diagnostics: gene panel, exome, or whole genome?

Genome Sequencing Demonstrates High Diagnostic Yield in Children with Undiagnosed Global Developmental Delay/intellectual Disability: A Prospective Study

Evaluating Genome Sequencing Strategies: Trio, Singleton, and Standard Testing in Rare Disease Diagnosis

Multiple molecular diagnoses in the field of intellectual disability and congenital anomalies: 3.5% of all positive cases

Systematic evaluation of genome sequencing for the diagnostic assessment of autism spectrum disorder and fetal structural anomalies

Diagnostic yield of exome and genome sequencing after non-diagnostic multi-gene panels in patients with single-system diseases

Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions

Marked Yield of Re-Evaluating Phenotype and Exome/target Sequencing Data in 33 Individuals with Intellectual Disabilities

Diagnostic genome sequencing improves diagnostic yield: a prospective single-centre study in 1000 patients with inherited eye diseases

Real-world diagnostic outcomes and cost-effectiveness of genome-wide sequencing for developmental and seizure disorders: evidence from Canada

Uncovering recessive alleles in rare Mendelian disorders by genome sequencing of 174 individuals with monoallelic pathogenic variants

The performance of genome sequencing as a first-tier test for neurodevelopmental disorders

Detection of Clinically Relevant Genetic Variants in Autism Spectrum Disorder by Whole-Genome Sequencing

The diagnostic yield, candidate genes, and pitfalls for a genetic study of intellectual disability in 118 middle eastern families

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Clinical exome sequencing data from patients with inborn errors of immunity: Cohort level diagnostic yield and the benefit of systematic reanalysis

Retrospective file review shows limited genetic services fails most patients - an argument for the implementation of exome sequencing as a first-tier test in resource-constraint settings

Exome and genome sequencing in a heterogeneous population of patients with rare disease: Identifying predictors of a diagnosis